[1]王张立,吴晓旭,崔阳,等.胶质母细胞瘤组织RBM8A表达与病人预后及替莫唑胺化疗敏感性的关系[J].中国临床神经外科杂志,2022,27(06):468-470473.[doi:10.13798/j.issn.1009-153X.2022.06.011]
　WANG Zhang-li,WU Xiao-xu,CUI Yang,et al.Relationship between the RBM8A expression in glioblastoma tissues and the prognosis and sensitivity of temozolomide chemotherapy of patients with glioblastoma[J].,2022,27(06):468-470473.[doi:10.13798/j.issn.1009-153X.2022.06.011]
点击复制

胶质母细胞瘤组织RBM8A表达与病人预后及替莫唑胺化疗敏感性的关系()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年06期
页码:
468-470473
栏目:
论著
出版日期:
2022-06-30

文章信息/Info

Title:
Relationship between the RBM8A expression in glioblastoma tissues and the prognosis and sensitivity of temozolomide chemotherapy of patients with glioblastoma
文章编号:
1009-153X(2022)06-0468-03
作者:
王张立; 吴晓旭; 崔阳; 王丹妹; 包春艳
065201 河北廊坊，河北燕达医院神经外科（王张立、吴晓旭、崔阳、王丹妹、包春艳）
Author(s):
WANG Zhang-li;  WU Xiao-xu;  CUI Yang;  WANG Dan-mei;  BAO Chun-yan
Department of Neurosurgery, Hebei Yanda Hospital,Langfang 065201, China
关键词:
胶质母细胞瘤; RNA结合基序8A（RBM8A）; 生存预后; 替莫唑胺; 基因表达
Keywords:
Glioblastoma;  RNA binding motif 8A;  Survival prognosis;  Temozolomide
分类号:
R739.41;Q786
DOI:
10.13798/j.issn.1009-153X.2022.06.011
文献标志码:
A
摘要:
目的 探讨胶质母细胞瘤（GBM）组织RNA结合基序8A（RBM8A）蛋白表达与病人预后及替莫唑胺（TMZ）化疗敏感性的关系。方法 选取2015年6月至2020年6月手术切除的GBM组织130例及颅脑损伤减压术中切取的非肿瘤脑组织20例（对照），用免疫组化法检测组织RBM8A表达。术随访时间3~50个月，中位随访时间为12个月。结果 GBM组织RBM8A高表达率[86.15%（112/130）]明显高于对照组[20%（4/20）；P<0.05]。随访期间死亡98例，失访2例；多因素Cox回归分析显示，RBM8A高表达是GBM病人生存预后不良的独立危险因素（P<0.05）。生存曲线分析显示，RBM8A高表达GBM病人中位无复发生存时间和总生存时间均明显低于低表达病人（P<0.05）；RBM8A低表达GBM病人中，TMZ化疗病人无复发生存时间和总生存时间均明显高于未化疗病人（P<0.05）；TMZ化疗与RBM8A高表达GBM病人无复发生存时间和总生存时间无明显关系（P>0.05）。结论 GBM组织RBM8A呈高表达，与病人不良生存预后有关。检测RBM8A有助于评估GBM病人对TMZ化疗敏感性。
Abstract:
Objective To investigate the relationship between the RNA binding motif 8A (RBM8A) expression in glioblastoma tissues and the prognosis and sensitivity of temozolomide chemotherapy of patients with glioblastoma. Methods The RBM8A expressions were detected using immunohistochemicai staining in the glioblastoma tissues obtained from 130 patients with glioblastoma who underwent micorsurgery from January 2014 to June 2020 and in non-tumor cerebral tissues obtained from 20 patients with traumatic brain injury who underwent decompression (control group). The glioblastoma patients were followed up for 3~50 months, with an medium time of 12 months. Results The high expression rate of RBM8A in glioblastoma tissues [86.15% (112/130)] was significantly higher than that in control group [20% (4/20); P<0.05]. During the follow-up, 98 patients died and 2 were lost to follow-up. Multivariate Cox regression analysis showed that high expression of RBM8A was an independent risk factor for poor survival prognosis of glioblastoma patients (P<0.05). Survival curve analysis showed that the median recurrence-free survival time and overall survival time of glioblastoma patients with high expression of RBM8A were significantly lower than those of patients with low expression of RBM8A (P<0.05). Temozolomide chemotherapy had no significant effect on the recurrence-free survival time and overall survival time of glioblastoma patients with high RBM8A expression (P>0.05). Conclusions The expression of RBM8A in glioblastoma tissue is high, which is related to the poor survival prognosis of glioblastoma patients. Detection of RBM8A is helpful to assessing the sensitivity of glioblastoma patients to temozolomide chemotherapy.

参考文献/References:

[1] 王明明，唐瑞天. 胞外囊泡源性miRNA在胶质母细胞瘤中作用的研究进展[J]. 中国临床神经外科杂志，2021，26（1）：50-52.
[2] Islam M, Wijethilake N, Ren H. Glioblastoma multiforme prognosis: MRI missing modality generation, segmentation and radiogenomic survival prediction [J]. Comput Med Imaging Graph, 2021, 91: 101906.
[3] 左明堂，梁　嵘，李永强. RBM8A与恶性肿瘤相关性研究进展[J]. 中华肿瘤防治杂志，2019，26（2）：132-136.
[4] Mei N, Chen H, Zhao N, et al. A comprehensive pan-cancer analysis of RBM8A based on data mining [J]. J Oncol, 2021, 2021: 9983354.
[5] 田　伟，李　峰，张　彬. STRAP在人脑胶质瘤组织中的表达及临床意义[J]. 中国临床神经外科杂志，2020，25（8）：510-513.
[6] Abukar A, Wipplinger M, Hariharan A, et al. Double-stranded RNA structural elements holding the key to translational regulation in cancer: the case of editing in RNA-binding motif protein 8A [J]. Cells, 2021, 10(12): 3543.
[7] Supek F, Lehner B, Lindeboom RGH. To NMD or not to NMD: nonsense-mediated mRNA decay in cancer and other genetic diseases [J]. Trends Genet, 2021, 37(7): 657-668.
[8] Lin Y, Liang R, Qiu Y, et al. Expression and gene regulation network of RBM8A in hepatocellular carcinoma based on data mining [J]. Aging (Albany NY), 2019, 11(2): 423-447.
[9] Lv X, Cheng H. Prognostic value of increased expression of RBM8A in gastric cancer [J]. Braz J Med Biol Res, 2020, 53(4): e9290.
[10] Lin Y, Wei L, Hu B, et al. RBM8A promotes glioblastoma growth and invasion through the Notch/STAT3 pathway [J]. Front Oncol, 2021, 11: 736941.
[11] 甘　隆，卢海庆，李生华，等. RBM8A在膀胱尿路上皮癌中的表达及其意义[J]. 新医学，2018，49（3）：164-168.
[12] Liang R, Zhang J, Liu Z, et al. Mechanism and molecular network of RBM8A-mediated regulation of oxaliplatin resistance in hepatocellular carcinoma [J]. Front Oncol, 2020, 10: 585452.
[13] Nie E, Jin X, Miao F, et al. TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT [J]. Neuro Oncol, 2021, 23(3): 435-446.
[14] Benson R, Mallick S, Purkait S, et al. Glioblastoma with primitive neuroectodermal component treated with adjuvant radiotherapy and temozolomide: a pooled analysis of 23 patients [J]. Neurol India, 2021, 69(4): 856-860.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(06):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(06):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(06):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(06):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(06):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

备注/Memo

备注/Memo:
（2022-01-13收稿，2022-05-11修回）
基金项目：廊坊市科技支撑计划项目（2021013050）
通讯作者：包春艳，E-mail：1370668574@qq.com
更新日期/Last Update: 2022-07-31